Revision 1

Store at -20C

#59027

LRIG1 (E1U2B) Rabbit mAb

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H	Endogenous	140	Rabbit IgG	#Q96JA1	26018

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. *Do not aliquot the antibody.*

Specificity/Sensitivity

LRIG1 (E1U2B) Rabbit mAb recognizes endogenous levels of total LRIG1 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human LRIG1 protein.

Background

Leucine-rich immunoglobulin repeats 1 (LRIG1) is a type I transmembrane protein containing 15 leucine rich repeats and three immunoglobulin domains in the extracellular domain. Researchers characterize LRIG1 as a negative regulator of receptor tyrosine kinase signaling. In studies with ErbB family members and Met kinase, LRIG regulates signaling by increasing ubiquitination and lysosomal degradation of the receptors (1,2). Additional work indicates that LRIG1 plays a role in neurotropic signaling by negatively regulating Ret signaling (3,4). Expression profile studies demonstrate that LRIG1 is a marker in the quiescent population of stem cells in the intestine (5). Interestingly, the genetic ablation of one allele of LRIG1 in mice with an APC+/- background results in development of highly dysplastic adenomas, indicating a role for LRIG1 in tumor suppression (1). Indeed, down-regulation of LRIG1 is tentatively involved in tumor aggressiveness in several tumor types, including glioma (6), head and neck cancer (7), and cervical adenocarcinoma (8).

Background References

1. Powell, A.E. et al. (2012) *Cell* 149, 146-58.
2. Segatto, O. et al. (2011) *J Cell Sci* 124, 1785-93.
3. Shattuck, D.L. et al. (2007) *Mol Cell Biol* 27, 1934-46.
4. Ledda, F. et al. (2008) *J Neurosci* 28, 39-49.
5. Muñoz, J. et al. (2012) *EMBO J* 31, 3079-91.
6. Mao, F. et al. (2013) *Int J Oncol* 42, 1081-7.
7. Sheu, J.J. et al. (2013) *Oncogene* 33, 1375-84.
8. Muller, S. et al. (2013) *Int J Oncol* 42, 247-52.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human

Trademarks and Patents

Limited Uses

force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.